Immunome Inc. (IMNM) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 42 days, typically, give or take 15 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Tue, Mar 3, 2026 | after close | 62 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | after close | 42 | 8-K |
| Q4 FY2024 | Wed, Mar 19, 2025 | after close | 78 | 8-K |
What they guided beta
| Q3 FY2026 | "Investigational New Drug (IND) clearance received for IM-1340, a potential first-in-class solid tumor antibody-drug conjugate (ADC), with Phase 1 trial initiation expected by year-end 2026 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for the quarter ended September 30, 2026, and provided a business update." exhibit |
| Q3 FY2026 | "IM-1021 : The Phase 1 clinical trial of IM-1021 is ongoing, and Immunome expects to present an updated dataset at the 2026 American Society of Hematology (ASH) Annual Meeting on December 14, 2026." exhibit |
| Q3 FY2026 | "Preclinical ADC Pipeline : Immunome expects to submit an IND for IM-1335 in late 2026." exhibit |
| Q3 FY2026 | "Immunome expects its current cash position to fund operations into 2028." exhibit |
| Q2 FY2026 | "Immunome expects to present initial lymphoma data for IM-1021 in 2026." exhibit |
| Q2 FY2026 | "Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively." exhibit |
| Q2 FY2026 | "Immunome expects its current cash position to fund operations into 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IMNM
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IMNM
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/IMNM/"><img src="https://veritasdata.dev/embed/IMNM.svg" alt="IMNM earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/IMNM/)
Script
<script async src="https://veritasdata.dev/embed/IMNM.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IMNM"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.